Fox Run Management’s Blue Bird Corp BLBD Stock Holding History

Fox Run Management’s Portfolio BLBD Stock Details BLBD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,479	Closed	-$582K	–	925
2025 Q2	$582K	Buy	+13,479	New	+$513K	0.1%	399
2024 Q4	–	Sell	-5,273	Closed	-$253K	–	878
2024 Q3	$253K	Buy	+5,273	New	+$261K	0.06%	604

Other funds holding BLBD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fox Run Management's BLBD Position: Q3 2025 in Review

Fox Run Management sold out of Blue Bird Corp (BLBD) in Q3 2025, closing a stake of 13,479 shares — an estimated $582K sold.

Fox Run Management first reported a position in BLBD in Q3 2024 and held it in 2 quarters. The position peaked at $582K in Q2 2025. 269 funds tracked by Wall St. Rank hold BLBD as of Q3 2025.

Fox Run Management reported no remaining Blue Bird Corp position as of Q3 2025 after selling out during the quarter.
Fox Run Management sold 13,479 Blue Bird Corp shares in Q3 2025, an estimated $582K.
Fox Run Management first reported a position in Blue Bird Corp in Q3 2024 and held it in 2 quarters.
Fox Run Management's Blue Bird Corp position peaked at $582K in Q2 2025.
269 funds tracked by Wall St. Rank held Blue Bird Corp as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.